University of Thessaly (UTH)
Μελέτη επαγωγής αντισωματικών απαντήσεων μετά από εμβολιασμό έναντι SARS CoV-2 και συσχέτιση με το γενετικό υπόστρωμα των εμβολιασμένων ατόμων
Abstract
dc:descriptionThe COVID-19 pandemic caused severe health, social, and economic consequences, making the rapid development of effective therapeutic interventions as well as the distribution of vaccines essential for the protection and for limiting the spread of SARS-CoV-2 infection. The development of different types of vaccines and their distribution, often under emergency use authorization, limited the possibility for sufficient long-term study of the immune response and the factors that influence it. The aim of the present study was to evaluate the immunogenicity of the different types of vaccines that were approved and administered at the onset of the COVID-19 vaccination program in Greece, as well as to assess the effectiveness of the subsequent booster doses. In12addition, immune responses following vaccination were investigated in relation to various factors, such as age, comorbidities, and the genetic background of the participants, which may potentially influence them.A total of 827 individuals aged 19 to 107 years (mean age: 61.7 years), with different medical history, who received different vaccines, representing a broad spectrum of the population, were included in the study. A significant proportion of elderly individuals, residents of long-term care facilities, and populations with comorbidities were enrolled, allowing valuable conclusions to be drawn for different subgroups, particularly the vulnerable. Of the participants, 72.9% initially received a two-dose mRNA vaccine regimen, while the remainder were vaccinated with adenovirus vector-based vaccines, either as a single-dose or two-dose scheme. Booster doses administered thereafter were with mRNA vaccines, either with the original strain or, at the time of the second booster dose, with updated mRNA vaccines targeting circulating variants. Blood samples were collected at predefined time points throughout the study, covering an extended follow-up period.Data analysis showed that all vaccines under study induced positive antibody responses and mild adverse events. The mRNA vaccine proved superior both in terms of the intensity of IgG and IgA responses and in protection against severe disease. A gradual decline in antibody titers, particularly IgA, was observed up to day 180 after the first dose. Age and a history of prior COVID-19 infection were found to be significant modifiers of the intensity of the antibody response. Moreover, a correlation between humoral and cellular immunity was identified. Administration of a second and third booster dose significantly enhanced immune responses and reduced the risk of fatal disease, confirming the necessity of systematic booster vaccination, especially in elderly individuals and those with comorbidities. Furthermore, analysis of participants’ genetic background revealed that the presence of the rs1883832 (c.- 1T>C) polymorphism of the CD40 gene and the rs10813831 (c.19C>T) polymorphism of the DDX58 gene was associated with immune responses after vaccination.This study provided real-time data on the immunogenicity and effectiveness of COVID-19 vaccines from the start of the vaccination campaign up to the third booster dose. It highlighted the critical importance of booster doses for maintaining high levels of immune response, as well as the impact of demographic, clinical, and genetic factors of vaccinated individuals on immunity. These data may be used to inform the design and adaptation of public health strategies.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Voulgaridi, Ioanna
- Βουλγαρίδη, Ιωάννα
Subjects
dc:subject × 13Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61527